{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T21:05:11Z","timestamp":1793135111070,"version":"4.5.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T00:00:00Z","timestamp":1724630400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T00:00:00Z","timestamp":1724630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82200819"],"award-info":[{"award-number":["82200819"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20220605"],"award-info":[{"award-number":["BK20220605"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Jiangsu Innovative and Enterpreneurial Talent Programme","award":["JSSCBS20211600"],"award-info":[{"award-number":["JSSCBS20211600"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-024-12820-7","type":"journal-article","created":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T05:02:19Z","timestamp":1724648539000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["APOL6 predicts immunotherapy efficacy of bladder cancer by ferroptosis"],"prefix":"10.1186","volume":"24","author":[{"given":"Zhiwei","family":"Fan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiting","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuehai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuting","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiyao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijian","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialing","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyuan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,26]]},"reference":[{"issue":"1","key":"12820_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"12820_CR2","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.eururo.2021.09.026","volume":"81","author":"R Cathomas","year":"2022","unstructured":"Cathomas R, Lorch A, Bruins HM, Comperat EM, Cowan NC, Efstathiou JA, et al. The 2021 updated European association of urology guidelines on metastatic urothelial carcinoma. Eur Urol. 2022;81(1):95\u2013103.","journal-title":"Eur Urol"},{"issue":"1","key":"12820_CR3","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s00204-020-02911-2","volume":"95","author":"H Liu","year":"2021","unstructured":"Liu H, Gu J, Jin Y, Yuan Q, Ma G, Du M, et al. Genetic variants in N6-methyladenosine are associated with bladder cancer risk in the Chinese population. Arch Toxicol. 2021;95(1):299\u2013309.","journal-title":"Arch Toxicol"},{"issue":"7","key":"12820_CR4","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1038\/s41401-020-0400-z","volume":"41","author":"J Gao","year":"2020","unstructured":"Gao J, Wang WQ, Pei Q, Lord MS, Yu HJ. Engineering nanomedicines through boosting immunogenic cell death for improved cancer immunotherapy. Acta Pharmacol Sin. 2020;41(7):986\u201394.","journal-title":"Acta Pharmacol Sin"},{"issue":"2","key":"12820_CR5","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/s41401-022-00953-z","volume":"44","author":"JJ Ni","year":"2023","unstructured":"Ni JJ, Zhang ZZ, Ge MJ, Chen JY, Zhuo W. Immune-based combination therapy to convert immunologically cold tumors into hot tumors: an update and new insights. Acta Pharmacol Sin. 2023;44(2):288\u2013307.","journal-title":"Acta Pharmacol Sin"},{"issue":"4","key":"12820_CR6","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252\u201364.","journal-title":"Nat Rev Cancer"},{"key":"12820_CR7","doi-asserted-by":"publisher","first-page":"105709","DOI":"10.1016\/j.intimp.2019.105709","volume":"74","author":"Z Wang","year":"2019","unstructured":"Wang Z, Zhang B, Zhang C, Ren S, Wang W, Wang Y, et al. Effect of region on the outcome of patients receiving PD-1\/PD-L1 inhibitors for advanced cancer. Int Immunopharmacol. 2019;74:105709.","journal-title":"Int Immunopharmacol"},{"issue":"19","key":"12820_CR8","doi-asserted-by":"publisher","first-page":"12293","DOI":"10.1073\/pnas.192461099","volume":"99","author":"Y Iwai","year":"2002","unstructured":"Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA. 2002;99(19):12293\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"19","key":"12820_CR9","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1001\/jama.2020.17598","volume":"324","author":"AT Lenis","year":"2020","unstructured":"Lenis AT, Lec PM, Chamie K, Mshs MD. Bladder cancer: a review. JAMA. 2020;324(19):1980\u201391.","journal-title":"JAMA"},{"issue":"6","key":"12820_CR10","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/S1470-2045(21)00094-2","volume":"22","author":"EY Yu","year":"2021","unstructured":"Yu EY, Petrylak DP, O\u2019Donnell PH, Lee JL, van der Heijden MS, Loriot Y, et al. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV-201): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2021;22(6):872\u201382.","journal-title":"Lancet Oncol"},{"issue":"12","key":"12820_CR11","doi-asserted-by":"publisher","first-page":"e542","DOI":"10.1016\/S1470-2045(16)30406-5","volume":"17","author":"GT Gibney","year":"2016","unstructured":"Gibney GT, Weiner LM, Atkins MB. Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol. 2016;17(12):e542\u201351.","journal-title":"Lancet Oncol"},{"issue":"26","key":"12820_CR12","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443\u201354.","journal-title":"N Engl J Med"},{"issue":"4","key":"12820_CR13","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1158\/2159-8290.CD-20-1808","volume":"11","author":"L Bejarano","year":"2021","unstructured":"Bejarano L, Jordao MJC, Joyce JA. Therapeutic Targeting of the Tumor Microenvironment. Cancer Discov. 2021;11(4):933\u201359.","journal-title":"Cancer Discov"},{"key":"12820_CR14","doi-asserted-by":"publisher","first-page":"106856","DOI":"10.1016\/j.intimp.2020.106856","volume":"88","author":"H Zhou","year":"2020","unstructured":"Zhou H, Zhang H, Shi M, Wang J, Huang Z, Shi J. A robust signature associated with patient prognosis and tumor immune microenvironment based on immune-related genes in lung squamous cell carcinoma. Int Immunopharmacol. 2020;88:106856.","journal-title":"Int Immunopharmacol"},{"issue":"3","key":"12820_CR15","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","volume":"18","author":"J Galon","year":"2019","unstructured":"Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov. 2019;18(3):197\u2013218.","journal-title":"Nat Rev Drug Discov"},{"issue":"9","key":"12820_CR16","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1038\/s41416-021-01488-6","volume":"125","author":"TL Rose","year":"2021","unstructured":"Rose TL, Weir WH, Mayhew GM, Shibata Y, Eulitt P, Uronis JM, et al. Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experience. Br J Cancer. 2021;125(9):1251\u201360.","journal-title":"Br J Cancer"},{"issue":"7","key":"12820_CR17","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.ccell.2021.05.009","volume":"39","author":"L Pusztai","year":"2021","unstructured":"Pusztai L, Yau C, Wolf DM, Han HS, Du L, Wallace AM, et al. Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II\/III breast cancer: results from the adaptively randomized I-SPY2 trial. Cancer Cell. 2021;39(7):989\u2013998.e985.","journal-title":"Cancer Cell"},{"issue":"6","key":"12820_CR18","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.ccell.2022.05.005","volume":"40","author":"DM Wolf","year":"2022","unstructured":"Wolf DM, Yau C, Wulfkuhle J, Brown-Swigart L, Gallagher RI, Lee PRE, et al. Redefining breast cancer subtypes to guide treatment prioritization and maximize response: predictive biomarkers across 10 cancer therapies. Cancer Cell. 2022;40(6):609\u2013623.e606.","journal-title":"Cancer Cell"},{"issue":"2","key":"12820_CR19","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.ccell.2019.01.003","volume":"35","author":"TN Gide","year":"2019","unstructured":"Gide TN, Quek C, Menzies AM, Tasker AT, Shang P, Holst J, et al. Distinct immune cell populations define response to Anti-PD-1 monotherapy and anti-PD-1\/Anti-CTLA-4 combined therapy. Cancer Cell. 2019;35(2):238\u2013255.e236.","journal-title":"Cancer Cell"},{"issue":"12","key":"12820_CR20","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.1093\/annonc\/mdx518","volume":"28","author":"A Necchi","year":"2017","unstructured":"Necchi A, Joseph RW, Loriot Y, Hoffman-Censits J, Perez-Gracia JL, Petrylak DP, et al. Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study. Ann Oncol. 2017;28(12):3044\u201350.","journal-title":"Ann Oncol"},{"issue":"D1","key":"12820_CR21","doi-asserted-by":"publisher","first-page":"D729","DOI":"10.1093\/nar\/gky1094","volume":"47","author":"R Zheng","year":"2019","unstructured":"Zheng R, Wan C, Mei S, Qin Q, Wu Q, Sun H, et al. Cistrome Data Browser: expanded datasets and new tools for gene regulatory analysis. Nucleic Acids Res. 2019;47(D1):D729\u201335.","journal-title":"Nucleic Acids Res"},{"key":"12820_CR22","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S H\u00e4nzelmann","year":"2013","unstructured":"H\u00e4nzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 2013;14:7.","journal-title":"BMC Bioinformatics"},{"issue":"4","key":"12820_CR23","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.immuni.2013.10.003","volume":"39","author":"G Bindea","year":"2013","unstructured":"Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 2013;39(4):782\u201395.","journal-title":"Immunity"},{"key":"12820_CR24","first-page":"2579","volume":"9","author":"LVD Maaten","year":"2008","unstructured":"Maaten LVD, Hinton GE. Visualizing data using t-SNE. J Mach Learn Res. 2008;9:2579\u2013605.","journal-title":"J Mach Learn Res"},{"key":"12820_CR25","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1038\/ncomms3612","volume":"4","author":"K Yoshihara","year":"2013","unstructured":"Yoshihara K, Shahmoradgoli M, Martinez E, Vegesna R, Kim H, Torres-Garcia W, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612.","journal-title":"Nat Commun"},{"issue":"5","key":"12820_CR26","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","volume":"12","author":"AM Newman","year":"2015","unstructured":"Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453\u20137.","journal-title":"Nat Methods"},{"key":"12820_CR27","doi-asserted-by":"publisher","first-page":"e26476","DOI":"10.7554\/eLife.26476","volume":"6","author":"J Racle","year":"2017","unstructured":"Racle J, de Jonge K, Baumgaertner P, Speiser DE, Gfeller D. Simultaneous enumeration of cancer and immune cell types from bulk tumor gene expression data. eLife. 2017;6:e26476.","journal-title":"eLife"},{"issue":"1","key":"12820_CR28","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1186\/s13059-016-1113-y","volume":"17","author":"E Becht","year":"2016","unstructured":"Becht E, Giraldo NA, Lacroix L, Buttard B, Elarouci N, Petitprez F, et al. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol. 2016;17(1):249.","journal-title":"Genome Biol"},{"issue":"1","key":"12820_CR29","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13073-019-0638-6","volume":"11","author":"F Finotello","year":"2019","unstructured":"Finotello F, Mayer C, Plattner C, Laschober G, Rieder D, Hackl H, et al. Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data. Genome Med. 2019;11(1):34.","journal-title":"Genome Med"},{"issue":"W1","key":"12820_CR30","doi-asserted-by":"publisher","first-page":"W509","DOI":"10.1093\/nar\/gkaa407","volume":"48","author":"XS Liu","year":"2020","unstructured":"Liu XS, Li B, Chen Q, Li J, Cohen D, Zeng Z, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020;48(W1):W509\u201314.","journal-title":"Nucleic Acids Res"},{"issue":"6","key":"12820_CR31","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon A, Birger C, Thorvaldsd\u00f3ttir H, Ghandi M, Mesirov Jill P, Tamayo P. The molecular signatures database hallmark gene set collection. Cell Syst. 2015;1(6):417\u201325.","journal-title":"Cell Syst"},{"issue":"1","key":"12820_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","volume":"39","author":"DS Chen","year":"2013","unstructured":"Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1\u201310.","journal-title":"Immunity"},{"issue":"1","key":"12820_CR33","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.celrep.2016.12.019","volume":"18","author":"P Charoentong","year":"2017","unstructured":"Charoentong P, Finotello F, Angelova M, Mayer C, Efremova M, Rieder D, et al. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep. 2017;18(1):248\u201362.","journal-title":"Cell Rep"},{"issue":"W1","key":"12820_CR34","doi-asserted-by":"publisher","first-page":"W322","DOI":"10.1093\/nar\/gkz397","volume":"47","author":"G Weng","year":"2019","unstructured":"Weng G, Wang E, Wang Z, Liu H, Zhu F, Li D, et al. HawkDock: a web server to predict and analyze the protein-protein complex based on computational docking and MM\/GBSA. Nucleic Acids Res. 2019;47(W1):W322\u201330.","journal-title":"Nucleic Acids Res"},{"issue":"9","key":"12820_CR35","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/j.str.2020.06.006","volume":"28","author":"IT Desta","year":"2020","unstructured":"Desta IT, Porter KA, Xia B, Kozakov D, Vajda S. Performance and its limits in rigid body protein-protein docking. Structure (London, England: 1993). 2020;28(9):1071\u20131081.e1073.","journal-title":"Structure (London, England: 1993)"},{"issue":"7873","key":"12820_CR36","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","volume":"596","author":"J Jumper","year":"2021","unstructured":"Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, et al. Highly accurate protein structure prediction with AlphaFold. Nature. 2021;596(7873):583\u20139.","journal-title":"Nature"},{"issue":"10","key":"12820_CR37","doi-asserted-by":"publisher","first-page":"2626","DOI":"10.1021\/ci4002475","volume":"53","author":"M Ylilauri","year":"2013","unstructured":"Ylilauri M, Pentikainen OT. MMGBSA as a tool to understand the binding affinities of filamin-peptide interactions. J Chem Inf Model. 2013;53(10):2626\u201333.","journal-title":"J Chem Inf Model"},{"issue":"W1","key":"12820_CR38","doi-asserted-by":"publisher","first-page":"W234","DOI":"10.1093\/nar\/gkz240","volume":"47","author":"G Zhou","year":"2019","unstructured":"Zhou G, Soufan O, Ewald J, Hancock REW, Basu N, Xia J. NetworkAnalyst 3.0: a visual analytics platform for comprehensive gene expression profiling and meta-analysis. Nucleic Acids Res. 2019;47(W1):W234\u201341.","journal-title":"Nucleic Acids Res"},{"key":"12820_CR39","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.tox.2019.05.003","volume":"423","author":"X Zhao","year":"2019","unstructured":"Zhao X, Wu Y, Li J, Li D, Jin Y, Zhu P, et al. JNK activation-mediated nuclear SIRT1 protein suppression contributes to silica nanoparticle-induced pulmonary damage via p53 acetylation and cytoplasmic localisation. Toxicology. 2019;423:42\u201353.","journal-title":"Toxicology"},{"issue":"1","key":"12820_CR40","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1186\/s40425-019-0745-3","volume":"7","author":"AC Bretz","year":"2019","unstructured":"Bretz AC, Parnitzke U, Kronthaler K, Dreker T, Bartz R, Hermann F, et al. Domatinostat favors the immunotherapy response by modulating the tumor immune microenvironment (TIME). J Immunother Cancer. 2019;7(1):294.","journal-title":"J Immunother Cancer"},{"issue":"7","key":"12820_CR41","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1158\/2326-6066.CIR-15-0274","volume":"4","author":"RF Sweis","year":"2016","unstructured":"Sweis RF, Spranger S, Bao R, Paner GP, Stadler WM, Steinberg G, et al. Molecular drivers of the non-T-cell-Inflamed tumor microenvironment in urothelial bladder cancer. Cancer Immunol Res. 2016;4(7):563\u20138.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"12820_CR42","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1158\/1541-7786.21.3.1","volume":"3","author":"Z Liu","year":"2005","unstructured":"Liu Z, Lu H, Jiang Z, Pastuszyn A, Hu CA. Apolipoprotein l6, a novel proapoptotic Bcl-2 homology 3-only protein, induces mitochondria-mediated apoptosis in cancer cells. Mol Cancer Res. 2005;3(1):21\u201331.","journal-title":"Mol Cancer Res"},{"issue":"5","key":"12820_CR43","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1101\/gr.085647.108","volume":"19","author":"EE Smith","year":"2009","unstructured":"Smith EE, Malik HS. The apolipoprotein L family of programmed cell death and immunity genes rapidly evolved in primates at discrete sites of host-pathogen interactions. Genome Res. 2009;19(5):850\u20138.","journal-title":"Genome Res"},{"issue":"3","key":"12820_CR44","doi-asserted-by":"publisher","first-page":"a028480","DOI":"10.1101\/cshperspect.a028480","volume":"11","author":"E Alspach","year":"2019","unstructured":"Alspach E, Lussier DM, Schreiber RD. Interferon gamma and Its Important roles in promoting and inhibiting spontaneous and therapeutic cancer immunity. Cold Spring Harb Perspect Biol. 2019;11(3):a028480.","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"31","key":"12820_CR45","doi-asserted-by":"publisher","first-page":"27389","DOI":"10.1074\/jbc.M110.210245","volume":"286","author":"S Zhaorigetu","year":"2011","unstructured":"Zhaorigetu S, Yang Z, Toma I, McCaffrey TA, Hu CA. Apolipoprotein L6, induced in atherosclerotic lesions, promotes apoptosis and blocks Beclin 1-dependent autophagy in atherosclerotic cells. J Biol Chem. 2011;286(31):27389\u201398.","journal-title":"J Biol Chem"},{"issue":"5","key":"12820_CR46","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","volume":"149","author":"SJ Dixon","year":"2012","unstructured":"Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149(5):1060\u201372.","journal-title":"Cell"},{"key":"12820_CR47","doi-asserted-by":"publisher","first-page":"113524","DOI":"10.1016\/j.biopha.2022.113524","volume":"153","author":"Y Wang","year":"2022","unstructured":"Wang Y, Zhang Z, Sun W, Zhang J, Xu Q, Zhou X, et al. Ferroptosis in colorectal cancer: potential mechanisms and effective therapeutic targets. Biomed Pharmacother. 2022;153:113524.","journal-title":"Biomed Pharmacother"},{"key":"12820_CR48","doi-asserted-by":"publisher","first-page":"628988","DOI":"10.3389\/fphar.2021.628988","volume":"12","author":"Z Fan","year":"2021","unstructured":"Fan Z, Cai L, Wang S, Wang J, Chen B. Baicalin prevents myocardial ischemia\/reperfusion injury through inhibiting ACSL4 mediated ferroptosis. Front Pharmacol. 2021;12:628988.","journal-title":"Front Pharmacol"},{"issue":"2","key":"12820_CR49","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1002\/cac2.12250","volume":"42","author":"L Zhao","year":"2022","unstructured":"Zhao L, Zhou X, Xie F, Zhang L, Yan H, Huang J, et al. Ferroptosis in cancer and cancer immunotherapy. Cancer Commun (Lond). 2022;42(2):88\u2013116.","journal-title":"Cancer Commun (Lond)"},{"issue":"11","key":"12820_CR50","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1038\/s41419-021-04306-2","volume":"12","author":"Y Sun","year":"2021","unstructured":"Sun Y, Berleth N, Wu W, Schlutermann D, Deitersen J, Stuhldreier F, et al. Fin56-induced ferroptosis is supported by autophagy-mediated GPX4 degradation and functions synergistically with mTOR inhibition to kill bladder cancer cells. Cell Death Dis. 2021;12(11):1028.","journal-title":"Cell Death Dis"},{"issue":"1","key":"12820_CR51","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1186\/s12967-023-04753-9","volume":"21","author":"Y Liu","year":"2023","unstructured":"Liu Y, Yang Y, Ni F, Tai G, Yu C, Jiang X, et al. Research on radiotherapy related genes and prognostic target identification of rectal cancer based on multi-omics. J Transl Med. 2023;21(1):856.","journal-title":"J Transl Med"},{"issue":"4","key":"12820_CR52","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1016\/j.jaci.2023.11.914","volume":"153","author":"X Liu","year":"2024","unstructured":"Liu X, Chan VS, Smith KG, Ming C, Or CS, Tsui FT, et al. Recapitulating primary immunodeficiencies with expanded potential stem cells: proof of concept with STAT1 gain of function. J Allergy Clin Immunol. 2024;153(4):1125\u201339.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"12820_CR53","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.ccell.2022.02.003","volume":"40","author":"P Liao","year":"2022","unstructured":"Liao P, Wang W, Wang W, Kryczek I, Li X, Bian Y, et al. CD8(+) T cells and fatty acids orchestrate tumor ferroptosis and immunity via ACSL4. Cancer Cell. 2022;40(4):365\u2013378 e366.","journal-title":"Cancer Cell"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-12820-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-024-12820-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-12820-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T17:03:42Z","timestamp":1724691822000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-024-12820-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,26]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["12820"],"URL":"https:\/\/doi.org\/10.1186\/s12885-024-12820-7","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,26]]},"assertion":[{"value":"20 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1046"}}